BIOHealthcare · Medical DevicesThe 5 Wall Street analysts covering Bio-Rad Laboratories, Inc. hold a median 12-month price target of $330 — -14.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 5 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Bio-Rad Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (44): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −14.5% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $370 → $390 |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $300 → $330 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | $320 → $370 |
| 5 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $310 → $330 |
| 15 May 2026 | RBC Capital | Reinstates | Outperform | $320 |
| 1 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 7 Apr 2026 | Citigroup | Downgrade | Neutral | — |
| 16 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 30 Oct 2025 | Citigroup | Maintains | Buy | — |
| 30 Oct 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 1 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 1 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 June 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 2 May 2025 | Citigroup | Maintains | Buy | — |
| 2 May 2025 | RBC Capital | Maintains | Outperform | — |
| 2 May 2025 | UBS | Maintains | Buy | — |
| 17 Apr 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 12 Feb 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 Jan 2025 | RBC Capital | Reiterates | Outperform | — |
| 9 Dec 2024 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Bio-Rad Laboratories, Inc. returned +33.4% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 16% of US stocks
Cheaper than 32% of US stocks
Cheaper than 58% of US stocks
Cheaper than 13% of US stocks
Higher than 27% of US stocks
Higher than 55% of US stocks
Higher than 66% of US stocks
Higher than 66% of US stocks
Higher than 67% of US stocks
Higher than 50% of US stocks
Higher than 56% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bio-Rad Laboratories, Inc. has a market value of $10.3B and an enterprise value of $10.1B.
Revenue in the twelve months to 30 June 2026: $2.6B. The latest quarter shrank 0.1% year on year.
Net income over the same four quarters: $222.4M, a 8.6% net margin.
Diluted earnings per share, trailing twelve months: $8.25.
Free cash flow in the twelve months to 30 June 2026: $353.1M.
Bio-Rad Laboratories, Inc. spent $132.7M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 47.0×; forward P/E: 38.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Bio-Rad Laboratories, Inc. employs 7,450 people — $348K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bio-Rad Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bio-Rad (BIO) reported earnings 30 days ago, and its stock has risen 11.7% since that report. The article examines whether the shares can sustain this upward momentum going forward.
Why it matters — A Bio-Rad watcher would care because the piece assesses whether the stock's post-earnings gains are likely to persist, a key signal for investors following the company.
Bio-Rad Laboratories announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat during Wells Fargo's 21st Annual Healthcare Conference on September 9, 2026, at 3:45 PM Eastern Time. A live webcast and replay of the event will be available in the Investor Relations section.
Why it matters — Bio-Rad watchers would be interested because the CFO's appearance at a major healthcare conference offers an opportunity for investors to hear directly about the company's outlook and strategy.
Zacks discusses Bio-Rad Laboratories, noting that its digital PCR gains and recurring diagnostics base support growth, while a 40.2X forward price-to-earnings ratio and a muted 2026 outlook keep valuation risk in focus.
Why it matters — A BIO watcher would care because the report highlights both the company's growth drivers and the valuation concerns that could influence how its stock is viewed.
Bio-Rad Laboratories' stock rose 19.1% over the past month, a rally supported by gains in digital PCR and steadier diagnostics demand. However, weak Life Science demand and a rich valuation pose potential challenges to sustaining the momentum.
Why it matters — The report highlights both the recent strength in BIO's share price and the mixed business conditions—growth in diagnostics offset by soft Life Science demand—that investors would watch when assessing its sustainability.
Zacks Investment Research highlights the importance of examining Bio-Rad's (BIO) international revenue trends when evaluating the stock, noting how these figures influence Wall Street forecasts.
Why it matters — BIO watchers would care because international revenue trends can affect analyst forecasts and expectations for the company's stock performance.
The 5 Wall Street analysts covering Bio-Rad Laboratories, Inc. have a median 12-month price target of $330, with estimates ranging from $280 to $390. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Bio-Rad Laboratories, Inc., 1 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bio-Rad Laboratories, Inc. 90 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Sept 2026, Bio-Rad Laboratories, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies -14.5% from the last close, and Ticker Nerd's factor model ranks Bio-Rad Laboratories, Inc. 90 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bio-Rad Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $390 over the next 12 months.
Bio-Rad Laboratories, Inc. returned +33.4% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing.
The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?". Bio-Rad (BIO) reported earnings 30 days ago, and its stock has risen 11.7% since that report. The article examines whether the shares can sustain this upward momentum going forward.
Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing. Bio-Rad Laboratories Inc. serves two main business segments: Life Science and Clinical Diagnostics. Its Life Science portfolio includes instruments, reagents, consumables, software, and content used to separate, purify, identify, and analyze biological materials such as cells, proteins, and nucleic acids. Its Clinical Diagnostics offerings include test systems, test kits, informatics tools, and quality controls used in areas such as diabetes monitoring, blood typing, infectious disease testing, autoimmune disorders, and genetic analysis. The company’s products are used by universities, hospitals, public health organizations, commercial laboratories, biotechnology firms, pharmaceutical companies, and food and environmental testing customers. Headquartered in Hercules, California, Bio-Rad Laboratories Inc. is recognized as a global supplier of tools that support scientific discovery and diagnostic decision-making.
CEO Mr. Norman D. Schwartz · 7,450 employees · United States · https://www.bio-rad.com
